1.
- Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE" / Sufliarsky J.. Onkológia. - ISSN 1336-8176. - Roč. 12, č. 5 (2017), s. 379
- C 3069